Different forms of the condition can "vary in severity, but colitis is especially concerning when it becomes chronic," says Dr. Jason Nagata, a pediatrician at UCSF Benioff Children’s Hospital in San ...

Ulcerative Colitis (UC) is a chronic inflammatory bowel disease affecting the colon lining, and its incidence is rising globally, especially in industrialized countries. The causes of UC are ...

THE physician who is caring for the female patient with chronic ulcerative colitis is occasionally asked about the advisability of child-bearing. Again, he may have the problem of treating a pregna ...

Ulcerative Colitis: Helping Patients Live With Chronic Disease ... In the same way, encouraging patients to be physically active can be helpful in developing a can-do attitude.

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).. The approval was based ...

Causes of constipation in ulcerative colitis can range from not eating enough fiber to medication side effects. Here’s how to get relief.

Chronic active colitis with granulomatous inflammation and Paneth cell metaplasia was present in 12/33 (36%) patients with biopsy-proven GVHD, 4/6 (67%) ...

The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of patients with moderately to severely active ulcerative colitis, according to a ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA ® showed highly statistically significant rates of endoscopic remission at one year in the ...

The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of ...

Tremfya is the first and only fully-human, dual-acting monoclonal antibody targeting IL-23 and CD64 to be approved for the treatment of moderately to severely active ulcerative colitis. The FDA has ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the ...